LOS ANGELES, Dec. 19, 2014 /PRNewswire/ -- Canopus BioPharma
Inc. (OTC Pink: CBIA) today announces that it has completed crucial
research in confirming efficacy of a prescription drug: CB008
for Ebola Virus inhibition.
Laboratories at the Texas Biomedical Research Institute in San
Antonio Texas have demonstrated complete in-vitro
inhibition of the live Ebola Virus strain Zaire at concentrations of CB008 that are
achievable by oral administration. CB008 is only one of a family of
prescription drugs which has been demonstrated by Canopus BioPharma
to have potential in preventing Hemorrhagic syndrome and inhibiting
Ebola Viral replication.
CB008 is an in-house codename for a well-established
prescription drug first approved by the FDA in the early 1980's for
other medical indications. CB008 is an effective, safe
treatment for Ebola Virus. Canopus BioPharma has signed a
confidential agreement with a major pharmaceutical company who are
reviewing the results and the possibility of expediting an Ebola
non-human primate study. Following this, CB008 can progress to a
human Ebola patient clinical trial in West Africa.
According to the CDC, the 2014 Ebola Virus epidemic is the
largest in history and is effecting multiple countries. In
this epidemic, 1 in 2 people who get the disease die from
it. It can take up to 21 days for an infected person to
develop symptoms from it. The highly contagious virus is
spread through contact with an infected persons blood or body
fluids."What we have shown by the use of CB008 in tissue culture is
how vulnerable these Ebola viruses are when you interfere with
their mechanism of creating havoc both to epithelial cells and to
the immune system," said Dr. Leo
Shanahan-Prendergast from Canopus BioPharma Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/canopus-biopharma-inc-announces-positive-results-from-an-in-vitro-live-ebola-virus-study-300012346.html
SOURCE Canopus BioPharma Inc.
